Literature DB >> 16009693

Chemoradiotherapy for colorectal cancer.

N Andre1, W Schmiegel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16009693      PMCID： PMC1774863          DOI： 10.1136/gut.2004.062745

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  57 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.

Authors:  Cornelis J A Punt; Attila Nagy; Jean-Yves Douillard; Arie Figer; Torben Skovsgaard; John Monson; Carlo Barone; George Fountzilas; Hanno Riess; Eugene Moylan; Delyth Jones; Juergen Dethling; Jessica Colman; Lorna Coward; Stuart MacGregor
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

3.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

4.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

5.  Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group.

Authors:  Mandy Van Den Brink; Wilbert B Van Den Hout; Anne M Stiggelbout; Elma Klein Kranenbarg; Corrie A M Marijnen; Cornelis J H Van De Velde; Job Kievit
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

6.  Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group.

Authors:  J F Bosset; G Calais; A Daban; C Berger; L Radosevic-Jelic; P Maingon; E Bardet; M Pierart; A Briffaux
Journal:  Eur J Cancer       Date:  2004-01       Impact factor: 9.162

7.  Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

Authors:  Axel Grothey; Daniel Sargent; Richard M Goldberg; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

8.  Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.

Authors:  C-H Köhne; J Wils; M Lorenz; P Schöffski; R Voigtmann; C Bokemeyer; M Lutz; C Kleeberg; K Ridwelski; R Souchon; M El-Serafi; U Weiss; O Burkhard; H Rückle; M Lichnitser; T Langenbuch; W Scheithauer; B Baron; M L Couvreur; H J Schmoll
Journal:  J Clin Oncol       Date:  2003-09-08       Impact factor: 44.544

Review 9.  Epithelial growth factor receptor interacting agents.

Authors:  Jose Baselga; Joan Albanell
Journal:  Hematol Oncol Clin North Am       Date:  2002-10       Impact factor: 3.722

Review 10.  Rectal cancer: Preoperative versus postoperative irradiation as a component of adjuvant treatment.

Authors:  Leonard L Gunderson; Michael G Haddock; Steven E Schild
Journal:  Semin Radiat Oncol       Date:  2003-10       Impact factor: 5.934
View more
  20 in total

1.  Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer.

Authors:  Yoshinaga Okugawa; Yuji Toiyama; Shusuke Toden; Hiroki Mitoma; Takeshi Nagasaka; Koji Tanaka; Yasuhiro Inoue; Masato Kusunoki; C Richard Boland; Ajay Goel
Journal:  Gut       Date:  2015-10-15       Impact factor: 23.059

2.  The effects of hyperbaric oxygen therapy on experimental colon anastomosis after preoperative chemoradiotherapy.

Authors:  Ramazan Yildiz; Mehmet Fatih Can; Gokhan Yagci; Taner Ozgurtas; Metin Guden; Mehmet Gamsizkan; Erkan Ozturk; Sadettin Cetiner
Journal:  Int Surg       Date:  2013 Jan-Mar

3.  Modified neutrophil-platelet score as a promising marker for stratified surgical and oncological outcomes of patients with gastric cancer.

Authors:  Yoshinaga Okugawa; Yuji Toiyama; Akira Yamamoto; Yusuke Omura; Kurando Kusunoki; Chengzeng Yin; Shozo Ide; Takahito Kitajima; Yuki Koike; Hiroyuki Fujikawa; Hiromi Yasuda; Yoshiki Okita; Junichiro Hiro; Shigeyuki Yoshiyama; Masaki Ohi; Toshimitsu Araki; Masato Kusunoki
Journal:  Surg Today       Date:  2019-09-04       Impact factor: 2.549

4.  Non-alcoholic fatty liver disease and colorectal cancer survival.

Authors:  Kana Wu; Mike Z Zhai; Erin K Weltzien; Elizabeth M Cespedes Feliciano; Jeffrey A Meyerhardt; Edward Giovannucci; Bette J Caan
Journal:  Cancer Causes Control       Date:  2018-11-15       Impact factor: 2.506

5.  Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer.

Authors:  Chin-Shaw Stella Tsai; Hung-Chang Chen; Jai-Nien Tung; Shung-Sheng Tsou; Tang-Yi Tsao; Ching-Fong Liao; Ying-Chun Chen; Chi-Yuan Yeh; Kun-Tu Yeh; Ming-Chung Jiang
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

6.  Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells.

Authors:  Anning Yin; Yingan Jiang; Xianfeng Zhang; Hesheng Luo
Journal:  Med Oncol       Date:  2009-05-05       Impact factor: 3.064

7.  miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.

Authors:  Lei Zhang; Karen Pickard; Veronika Jenei; Marc D Bullock; Amanda Bruce; Richard Mitter; Gavin Kelly; Christos Paraskeva; John Strefford; John Primrose; Gareth J Thomas; Graham Packham; Alex H Mirnezami
Journal:  Cancer Res       Date:  2013-08-15       Impact factor: 12.701

8.  Long noncoding RNA SH3PXD2A-AS1 promotes colorectal cancer progression by regulating p53-mediated gene transcription.

Authors:  Pingfu Hou; Tian Lin; Sen Meng; Meilin Shi; Fang Chen; Tao Jiang; Zhongwei Li; Minle Li; Sufang Chu; Junnian Zheng; Jin Bai
Journal:  Int J Biol Sci       Date:  2021-05-11       Impact factor: 6.580

9.  Correlations between cytoplasmic CSE1L in neoplastic colorectal glands and depth of tumor penetration and cancer stage.

Authors:  Cheng-Jeng Tai; Tzu-Cheng Su; Ming-Chung Jiang; Hung-Chang Chen; Shing-Chuan Shen; Woan-Ruoh Lee; Ching-Fong Liao; Ying-Chun Chen; Shu-Hui Lin; Li-Tzu Li; Ko-Hung Shen; Chung-Min Yeh; Kun-Tu Yeh; Ching-Hsiao Lee; Hsin-Yi Shih; Chun-Chao Chang
Journal:  J Transl Med       Date:  2013-01-31       Impact factor: 5.531

10.  Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival.

Authors:  Edward L Giovannucci; Kana Wu; Emilie S Zoltick; Stephanie A Smith-Warner; Chen Yuan; Molin Wang; Charles S Fuchs; Jeffrey A Meyerhardt; Andrew T Chan; Kimmie Ng; Shuji Ogino; Meir J Stampfer
Journal:  Br J Cancer       Date:  2021-07-15       Impact factor: 9.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.